From SPC expiry to first generic supply: the work in between, in the UK and Europe

Two dates that get confused

The exclusivity date, whether it is an SPC expiry, the end of market protection or a court judgment, is the first day on which a generic may lawfully be supplied. First supply is the day a wholesaler can actually buy it. In the UK and Germany the two are often days apart; in Italy, Spain or France they can be a year apart; in a small market where no generic company bothered, they never meet. The difference is the work below, and whether it was finished in time.

The authorisation: file at year eight, hold until year ten

A generic application may be submitted once eight years have passed from the reference product’s first EU authorisation, and the product may not be placed on the market until ten (eleven with a protected new indication). The studies behind the application, bioequivalence and the rest, are protected from patent infringement by the Bolar exemption. So the regulatory path is designed to let a generic be approved and waiting before the market opens.

Most generics come through the decentralised procedure, with one reference member state and the others assessing in parallel; from validation to the end of the procedure is around seven months on paper and nearer a year with clock stops, then a short national phase for each licence. UK applicants use the MHRA, with recognition routes that lean on an EU assessment. A company that files on the first permitted day will typically hold licences twelve to eighteen months before the exclusivity date; one that files late holds nothing.

Pricing, reimbursement and listing: the country-by-country part

This is where the calendars diverge.

United Kingdom. No price approval is needed. A generic is listed in the Drug Tariff; a new generic enters as Category C (priced by reference to a listed brand) or Category A, and is moved to Category M once there are enough suppliers for the NHSBSA to survey purchase prices, at which point the reimbursement price falls, often within a quarter. Pharmacies buy from wholesalers at market prices from day one. First supply can be the expiry date itself if the stock is in the country.

Germany. Prices are set by the company and published in the Lauer-Taxe on the 1st and 15th of each month, so a launch slots into a fortnightly cycle. Uptake is driven by the statutory insurers’ rebate contracts (tendered, typically for two years) and pharmacy substitution rules; a generic without a contract sells little, and the tender calendar does not wait for the expiry date.

France. A generic must be entered in the generic reference list (répertoire des groupes génériques) and priced by the CEPS, with reimbursement listing by the ministry; substitution follows the listing. The Transparency Directive caps each step at 90 days, or 180 for price and reimbursement together, but the clock starts when the file is complete.

Spain and Italy. Price and reimbursement decisions by the ministry and AIFA respectively, with publication in the official lists; reference-price groups form once generics are listed. Several months is normal; a product can be authorised and legally sellable with no reimbursed price, which in practice means no sales.

Nordics, Netherlands, hospital markets everywhere. Supply is by tender or preference policy: Denmark’s fortnightly re-bidding, Norway’s and Sweden’s substitution lists, the Dutch insurers’ preferred-product tenders, hospital tenders in most countries. A generic that misses the tender cycle around the expiry date waits for the next one.

Under today’s law, filing for pricing and reimbursement before the SPC expires can itself be treated as an act of infringement in some jurisdictions, which is what the nintedanib decision turned on. The EU pharmaceutical package extends the Bolar exemption to pricing, reimbursement and tenders, which will close that gap once it applies.

Product, packs and stock

The active ingredient must be qualified and in the dossier; a second source helps when the first is also supplying the originator. Each market needs its own pack: language, leaflet, national pack sizes, serialisation under the Falsified Medicines Directive, and in the UK a GB or UK-wide livery. Stock has to be manufactured, released and in the country before the date, and for a cold-chain or sterile product that lead time is months. The list of countries a generic company actually launches in on day one is, for most products, far shorter than the list it holds licences for.

The patent position, decided or gambled

All of the above assumes the compound SPC is the last obstacle. Where a secondary patent is asserted, the generic chooses between clearing the path in advance (a revocation action, typically started two to three years out) and launching at risk and facing an injunction application, a choice covered in its own explainer. The expiry date on the register is only the launch date if that choice has been made and has worked out.

Why it matters, by role

For a parallel trader, first generic supply in a country is the moment the price of the originator’s product there starts to move and the moment demand for imported originator stock falls; the expiry date is an early warning, the national listing is the signal.

For a buyer, the reimbursement mechanics (Category M in the UK, reference-price groups elsewhere) say when the price will drop, which is usually a quarter or two after first supply rather than on it; stock bought at the pre-expiry price in that window loses value fastest.

For a launch planner, the diagram is the plan: each row has an owner and a date, and the exclusivity date is the deadline for all of them.

MPA Search holds the exclusivity dates and the licence positions that fix the deadline; the national pricing mechanics belong to the country guides.